登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

Merck restructures R&D, licensing ops   

2009-09-02 17:59:36|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Merck restructures R&D, licensing ops in merger revamp

Merck has unveiled its new corporate structure and the top execs who will rule the pharma giant once the Schering-Plough merger is complete. It's pressing its biologics business into a division--dubbed Global Human Health-which will also include vaccines and prescription drugs. And Merck is touting a newly structured research operation that will be in charge of the global hunt for new licensing pacts.

Current Global Human Health chief Kenneth Frazier will head up the combined company's biggest division, with Peter Kim holding on to the top job at Merck Research Laboratories (MRL). Animal Health and Consumer Health Care will operate as separate business units.

"The new structure for MRL is designed to foster innovation while instilling greater accountability at all stages of the R&D process through two core functions:  1) discovery and pre-clinical development, and, 2) clinical development and regulatory affairs," said the company in a statement. "In addition, a new central franchise structure focused on portfolio management will be aligned with the company's Global Human Health division.  The new MRL will continue its focus on pursuing the best science around the globe through a Worldwide Licensing group."

Chemicals group Lonza sells Singapore unit to Roche

ZURICH — Swiss chemicals group Lonza said Monday it has signed a deal to sell a manufacturing facility in Singapore to a Roche-owned subsidiary for up to 360 million dollars (252 million euros).

The purchase price of the cell culture biologic manufacturing facility was 290 million dollars while an additional 70 million dollars would be paid up if certain milestones were met, Lonza said in a statement.

Swiss pharmaceutical giant Roche said the facility will be merged with an existing facility run by its subsidiary Genentech Singapore.

Some 230 Lonza employees at the site would also join Genentech Singapore.

http://www.google.com/hostednews/afp/article/ALeqM5iqDZGOfHcUQVLLJd8lsi72fljMtQ
Top 15 Bestselling Drugs of 2008
Ranking the best-selling branded drugs in the world is a bit like gathering the most popular kids in high school together in one room. The usual suspects are always there (in this case, that means Lipitor, Plavix, Seroquel, Effexor XR, et al.) until they graduate--or in this case, go off patent. Then they're suddenly missing from the chosen few. So take a close look at this year's crowd, ranked IMS Health using 2008 sales figures. In some cases, it'll be your last chance.
Lipitor

Maker: Pfizer
Script Rank: 1
Sales Rank: 1
2008 Sales: $7.77 billion

Nexium

Maker: AstraZeneca
Script Rank: 7
Sales Rank: 2
2008 Sales: $5.89 billion
Plavix

Maker: Bristol-Myers Squibb and Sanofi-Aventis
Script Rank: 11
Sales Rank: 3
2008 Sales: $4.83 billion 
Advair

Maker: GlaxoSmithKline
Script Rank: 20
Sales Rank: 3
2008 Sales: $4.38 billion 

Seroquel

Maker: AstraZeneca
Script Rank: 5
Sales Rank: 5
2008 Sales: $3.78 billion 
Singulair

Maker: Merck
Script Rank: 6
Sales Rank: 6
2008 Sales: $3.44 billion 

Enbrel

Maker: Amgen and Wyeth
Script Rank: 7
Sales Rank: 7
2008 Sales: $3.6 billion 
Neulasta

Maker: Amgen
Script Rank: 10
Sales Rank: 10
2008 Sales: $3.02 billion

Actos

Maker: Takeda
Script Rank: 100
Sales Rank: 8
2008 Sales: $3.11 billion 

Epogen

Maker: Amgen
Script Rank: 11
Sales Rank: 11
2008 Sales: $3.02 billion

Prevacid

Maker: Takeda
Script Rank: 31
Sales Rank: 9
2008 Sales: $3.09 billion

Abilify
Photo Credit: Bristol-Myers Squibb

Maker: Bristol-Myers Squibb and Otsuka America Pharmaceuticals
Script Rank: 117
Sales Rank: 12
2008 Sales: $3.1 billion

Remicade

Maker: Johnson & Johnson and Schering-Plough
Sales Rank: 13
2008 Sales: $3.1 billion

Maker: Wyeth
Script Rank: 23
Sales Rank: 14
2008 Sales: $3 billion

Lexapro

Maker: Forest Pharmaceuticals
Script Rank: 9
Sales Rank: 15
2008 Sales: $2.9 billion




  评论这张
 
阅读(439)| 评论(0)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018